中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (8): 608-613.doi: 10.3969/j.issn.1007-3969.2015.08.008

• 论著 • 上一篇    下一篇

乳腺癌新辅助化疗后腋窝及内乳前哨淋巴结活检研究

曹晓珊1,2,丛斌斌1,2,孙 晓1,邱鹏飞1,刘雁冰1,赵 桐1,陈 鹏1,王春建1,王永胜1   

  1. 1. 山东省肿瘤医院乳腺病中心,山东 济南 250117 ;
    2. 济南大学山东省医学科学院医学与生命科学学院,山东 济南 250200
  • 出版日期:2015-08-30 发布日期:2015-12-14
  • 通信作者: 王永胜 E-mail:wangysh2008@ aliyun.com
  • 基金资助:
    山东省自然科学基金重点项目(ZR2014HZ2003)。

A retrospective study of axillary and internal mammary sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy

CAO Xiaoshan1,2, CONG Binbin1,2, SUN Xiao1, QIU Pengfei1, LIU Yanbing1, ZHAO Tong1, CHEN Peng1, WANG Chunjian1, WANG Yongsheng1   

  1. 1.Breast Cancer Center, Shandong Cancer Hospital & Institute, Jinan Shandong 250117, China; 2.School of Medicine and Life Sciences, Jinan University-Shandong Academy of Medical Sciences, Jinan Shandong 250200, China
  • Published:2015-08-30 Online:2015-12-14
  • Contact: WANG Yongsheng E-mail: wangysh2008@ aliyun.com

摘要: 背景与目的:临床新辅助化疗(neoadjuvant chemotherapy,NAC)后腋窝淋巴结(axillary lymph node,ALN)转阴的患者腋窝前哨淋巴结活检(axillary sentinel lymph node biopsy, ASLNB)能否替代腋窝淋巴结清扫(axillary lymph node dissection,ALND)尚存在争议,且此前研究只评估ALN病理状况而未评估内乳淋巴结(internal mammary lymph node,IMLN)状况。本研究旨在评估NAC后乳腺癌患者接受ASLNB和内乳前哨淋巴结活检(internal mammary sentinel lymph node biopsy,IM-SLNB)的临床意义。方法:回顾性分析2012年1月—2014年12月山东省肿瘤医院乳腺病中心原发性乳腺癌(cT1-4N0-3M0)60例患者的临床资料,将患者分为3组:A组初始cN0且NAC后为ycN0,B组初始cN+且NAC后为ycN0,C组NAC后为ycN+。术前接受核素注射。术中A组和B组联合亚甲蓝行ASLNB。A组仅对腋窝前哨淋巴结(axillary sentinel lymph node,ASLN)阳性者行ALND;B组行ASLNB后转行ALND;C组直接行ALND。术前淋巴显像和(或)γ探测仪发现内乳前哨淋巴结(internal mammary sentinel lymph node,IM-SLN)的患者行IM-SLNB。结果:A组、B组和C组分别收集6例、45例和9例。A组ASLNB成功率为100%(6/6),仅1例ASLN阳性转行ALND。B组ASLNB成功率为100%(45/45),假阴性率为17.9%(5/28)。其中检出1枚、2枚和>2枚ASLN的假阴性率分别为27.3%(3/11)、20.0%(2/10)和0%(0/7)。C组所有患者ALN均有转移。IM-SLN总体显像率为63.3%(38/60)。IM-SLNB的总体成功率为97.4%(37/38),转移率为8.1%(3/37),并发症发生率为5.3%(2/38)。结论:对初始cN0且NAC后为ycN0者ASLN阴性时ASLNB可替代ALND;对初始cN+且NAC后为ycN0者,联合双示踪剂且检出>2枚ASLN可满足临床可接受的假阴性率(<10%);对NAC后仍为ycN+者应行ALND。NAC后IM-SLN显像者应行IM-SLNB,以获得完整分期、评估预后并指导术后放疗,有望完善病理完全缓解(pathological complete response,pCR)定义。

关键词: 乳腺癌, 新辅助化疗, 腋窝前哨淋巴结活检, 内乳前哨淋巴结活检

Abstract: Background and purpose: Whether axillary sentinel lymph node biopsy (ASLNB) could replace axillary lymph node dissection (ALND) in patients who converted after neoadjuvant chemotherapy (NAC) from cN+ to ycN0 is still contentious, and the previous study only evaluated the pathological status of ALN without internal mammary lymph node (IMLN) condition. This study is to evaluate roles of ASLNB and internal mammary sentinel lymph node biopsy (IM-SLNB) in breast cancer patients after NAC. Methods: From Jan. 2012 to Dec. 2014, 60 breast cancer cT1-4 N0-3M0 patients who were scheduled for neoadjuvant chemotherapy (NAC) and agreed to accept surgery after NAC from our department were enrolled into the retrospective study. Patients with cN0 before NAC and ycN0 after NAC underwent ASLNB (group A). Patients with cN+ received NAC and ycN0 after NAC (group B) were treated with ASLNB and ALND. Only patients whose clinical nodal status remained positive (ycN+) after NAC underwent ALND without ASLNB (group C). All the patients received radiotracer injection and patients in group A and group B received blue dye injection additionally. Meanwhile, IM-SLNB would be performed for all patients with IMSLN visualization. Results: The number of patients enrolled in group A, group B and group C was 6, 45 and 9 cases respectively. The accuracy rate of ASLNB in group A was 100% (6/6). Only one patient was axillary sentinel lymph node (ASLN) positive performed ALND. With combination of blue dye and radiolabeled colloid, the accuracy rate of ASLNB in group B was 100% (48/48) and the false negative rate (FNR) was 17.9% (5/28). The FNR in patients with 1, 2 and >2 SLNs examined was 27.3% (3/11), 20.0% (2/10) and 0% (0/7). All of the ALNs were positive in group C. The visualization rate of IM-SLN was 63.3% (38/60). The detection rate of IM-SLNB was 97.4% (37/38) and the metastasis rate was 8.1% (3/37). The incidence of complications was 5.3% (2/38). Conclusion: ASLNB can be performed either before or after preoperative chemotherapy for patients with cN0 disease. Among women with cN+ converted to ycN0 who had 3 or more SLNs examined, the FNR could return to be less than 10%. Those patients whose nodes are still ycN+ should perform ALND. IM-SLNB should be performed routinely in all breast cancer patients after NAC, for it might help to make clear of the nodal staging and the pathological status of IM-SLN and provide the accurate indication of radiation to the internal mammary area in case of under-stage and under-/over-treatment, expecting to develop the definition of pathological complete response (pCR). 

Key words: Breast neoplasm, Neoadjuvant chemotherapy, Axillary sentinel lymph node biopsy, Internal mammary sentinel lymph node biopsy